CNBC Business News Update - Market Midday: Markets Mixed, Bond Expert Warns Investors To Be 20% In Cash, Investors Wait For Retail Quarterly Results 11/17/25

Episode Date: November 17, 2025

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

I'm Jessica Eddinger, CNBC, Wall Street, starting a little turnaround this afternoon after all the major averages were in the red this morning. You've got the Dow down just six points this afternoon. Nike shares leading it lower. They're down one and a half percent. The S&P 500 index turned positive. It's up nine points. The NASDAQ also in the green now, up 66 points. Invidia shares are still lower. They're down 1.3 percent this afternoon. Bond star and billionaire Jeffrey Gunlock says he sees one of the least healthy stock markets of his career he's urging investors to make sure they're at least 20% in cash. Listen, we may wobble the year end. You know, I do think there's some, you know, worry about if the Fed is going to go or not.

I think they should do 25, but, you know, choppiness is likely to be the order of the day. But, you know, as I say, AI is a revolution that could bring about economies of scale that far exceed what we saw from the development of the Internet. That's Wharton Professor Jeremy Siegel on CNBC. Slate Stone's Aaron Gibbs tells CNBC, if you own a lot of tech stocks, evaluate and maybe take some profits. As you're coming to the year end and you're talking with your financial advisor, take some of those profits. maybe it might be time to reallocate, lighten up on some of those tech names as you go into 2026, because there are real concerns out there. Novo Nordisk with new pricing for weight loss drug Wagovi and diabetes drug Ozempic. Introductory doses of Novo Nordis drugs will be available for $199 per month.

That price increases to $349 per month after the first two months. Novo said the move will also help bring back customers who switch to compounded versions I during shortages. At CNBC's Joe Kernan, patients using the competitor, Eli Lilly's Zepbound for weight loss are paying $350 a month for the starter dose, and then $500 a month for higher doses. Alphabet shares were higher on news that Warren Buffett's Berkshire Hathaway has a position in the parent company of Google and YouTube. Big retail names reporting quarterly results this week, and they include Walmart, Target, and Home Depot, as they get ready for the holiday rush with Thanksgiving and Black Friday next week.

Lions Gates, Now You See Me Three, was number one at the weekend box office, beating Paramounts, The Running Man. Jessica Eddinger, CNBC. CNBC Podcasts. All your shows on the go. Ready when you are. Listen to CNBC wherever you get your podcasts.